Condition

Refractory WHO Grade 2 Glioma

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions8

Lead sponsors shown1

Clinical trials

3 shown

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888 · 2021-05-03

ACTIVE_NOT_RECRUITING

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13

ACTIVE_NOT_RECRUITING

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)NCT04195555 · 2020-07-20

ACTIVE_NOT_RECRUITING

Common interventions

Computed TomographyPROCEDURE1IvosidenibDRUG1Magnetic Resonance ImagingPROCEDURE1Positron Emission TomographyPROCEDURE1Radionuclide ImagingPROCEDURE1SelpercatinibDRUG1TipifarnibDRUG1X-Ray ImagingPROCEDURE1

Leading sponsors

National Cancer Institute (NCI)3

Trial status mix

ACTIVE_NOT_RECRUITING3

Phase mix

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.